Schedule 13G ownership disclosure

Karyopharm Therapeutics Inc

Common Stock, $0.0001 par value · CUSIP: 48576U205

Event date: 2025-06-30

Filing-level shares
450,436.0
Percent of class
5.2%
  • JPMORGAN CHASE & CO.

    Shares: 450,436.0 · Class: 5.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000019617-25-000528
Form type
SCHEDULE 13G
Filer
JPMORGAN CHASE & CO
CIK
CIK 19617
Filed
Jul 16, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub